A common renal disease, immunoglobulin A (IgA) nephropathy (IgAN), is associated with glomerular deposition of IgA1-containing immune complexes. IgA1 hinge region (HR) has up to six clustered Oglycans consisting of Ser/Thr-linked N-acetylgalactosamine with β1,3-linked galactose and variable sialylation. IgA1 glycoforms with some galactose-deficient (Gd) HR O-glycans play a key role in IgAN pathogenesis. The clustered and variable O-glycans make the IgA1 glycomic analysis challenging and better approaches are needed. Here, we report a comprehensive analytical workflow for IgA1 HR Oglycoform analysis. We combined an automated quantitative analysis of the HR O-glycopeptide profiles with sequential deglycosylation to remove all but Gd O-glycans from the HR. The workflow was tested using serum IgA1 from healthy subjects. Twelve variants of glycopeptides corresponding to the HR with three to six O-glycans were detected; nine glycopeptides carried up to three Gd O-glycans. Sites with Gd O-glycans were unambiguously identified by electron-transfer/higher-energy collision dissociation tandem mass spectrometry. Extracted ion chromatograms of isomeric glycoforms enabled quantitative assignment of Gd sites. The most frequent Gd site was T 236 , followed by S 230 , t 233 , t 228 , and S 232 . the new workflow for quantitative profiling of IgA1 HR O-glycoforms with site-specific resolution will enable identification of pathogenic IgA1 HR O-glycoforms in igAn.
α2,6-linked to GalNAc) 16 . Hence, the IgA1 HR O-glycoforms can potentially be highly diverse in terms of the glycan attachment sites, the number of O-glycan chains, and the glycan structures.
Regarding the function of IgA1 HR O-glycans, HR O-glycans of secretory IgA1 (sIgA) serve as bacterial interaction sites, enabling IgA to participate in innate immunity in addition to adaptive immunity 17 . From that point of view, N-and O-glycosylation analysis of sIgA isolated from human colostrum and saliva was previously performed [18] [19] [20] . In serum IgA1, altered IgA1 O-glycosylation has been reported in pregnancy and several IgA-related diseases, including IgA nephropathy (IgAN) and IgA vasculitis with nephritis [21] [22] [23] [24] . In IgAN, galactosylation of the HR O-glycoforms in the serum IgA1 and glomerular IgA1 is reduced. Consequently, the serum levels of IgA1 with Gal-deficient (Gd) O-glycans, with terminal or sialylated GalNAc residues, are elevated in IgAN [25] [26] [27] . These observations stem from a lectin-based enzyme-linked immunosorbent assay (ELISA) using Helix aspersa agglutinin (HAA), a lectin specifically recognizing terminal GalNAc. Furthermore, IgA1 in glomerular immunodeposits is enriched for Gd-IgA1 glycoforms, as revealed by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and lectin ELISA 28, 29 . There are some studies reporting that differential serum IgA1 HR O-glycosylation impacts pathogenesis of IgAN and disease progression. For example, hypo-galactosylated IgA may be prone to self-aggregation and, when recognized by autoantibodies specific for galactose-deficient IgA1 (Gd-IgA1), it forms immune complexes [30] [31] [32] . Furthermore, agalactosylated IgA1 has increased affinity for extracellular matrix proteins, such as fibronectin and type IV collagen [30] [31] [32] .
Recently, monoclonal antibodies (mAbs) specific for Gd-IgA1 were developed and their high reactivity with serum IgA1 from IgAN patients was demonstrated 33, 34 . Furthermore, immunostaining with these mAbs revealed that the glomerular IgA1 in IgAN and IgA vasculitis with nephritis contain Gd-IgA1 35 . However, O-glycoforms of IgA1 in renal immunodeposits have not been characterized at the molecular level. This type of analysis to elucidate the O-glycan structure of IgA1 involved in the pathogenesis of IgAN will require not only quantitative O-glycopeptide profiling but also determination of Gd O-glycan attachment sites.
We have previously characterized IgA1 HR O-glycan micro-heterogeneity and attachment sites [36] [37] [38] . The current standard analysis of IgA1 O-glycan heterogeneity involves two steps: (1) profiling of IgA1 HR O-glycopeptides by liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to identify IgA1 HR O-glycoforms; and (2) analyzing HR fragments generated with an IgA protease(s) by using electron-transfer dissociation (ETD) tandem MS to identify the sites of O-glycan attachment in individual IgA1 HR O-glycoforms. One limitation of this protocol is the throughput, as the Gd O-glycan attachment sites should be assigned in all O-glycoforms. In this study, we report a new workflow for a high-throughput glycomic analyses of IgA1 O-glycosylation. This workflow includes quantitative assessment of the attachment sites of Gd O-glycans in IgA1 HR.
Figure 1.
Human immunoglobulin A1 (IgA1) structure and the hinge-region (HR) O-glycans. (a) IgA1 structure. The major differences between IgA1 and IgA2 subclasses are in the HR. Human IgA1 HR is longer than that of IgA2, and with mucin-type clustered core 1 O-glycans attached (open circles). The HR usually has three to six O-glycan chains attached to some of the nine potential O-glycosylation sites. Six serine (S) and threonine (T) residues denoted in red are frequently glycosylated. (b) O-glycan variants of the serum IgA1. Nacetylgalactosamine (GalNAc) is attached to S/T residues in the HR. The O-glycan chain can be extended by the attachment of galactose (Gal) to GalNAc residues. GalNAc or Gal can be sialylated. Due to the step-wise nature of the O-glycosylation process, the IgA1-HR O-glycoforms exhibit a wide heterogeneity. An efficient neuraminidase treatment can reduce the complexity of IgA1-HR O-glycans to a mixture of disaccharides (Gal-GalNAc) and/or monosaccharides (GalNAc). NeuAc, N-acetylneuraminic acid.
Results

Development of a new protocol and bioinformatics solution for IgA1 HR O-glycoform profiling by sequential deglycosylation.
To enhance throughput of IgA1 O-glycome quantitative profiling with site-specific resolution, we developed the sequential deglycosylation protocol. This protocol enables a quantitative removal of all but Gd O-glycans from the HR by using O-glycanase after neuraminidase treatment. To optimize efficiency of O-glycanase treatment, we compared two different O-glycanase preparations using polymeric IgA1 myeloma protein; one O-glycanase from Streptococcus pneumoniae and another one from Enterococcus faecalis. O-glycanase from E. faecalis showed superior efficacy, as only 0.42% of disaccharides remained on HR after the enzyme treatment, as compared to 63.94% for S. pneumoniae enzyme. ( Supplementary Table S1 ). After the removal of all GalNAc-Gal disaccharides from IgA1, HR (glyco)peptides were produced by digestion with trypsin and analyzed by LC-HRMS with ETD combined with supplemental higher energy collision dissociation (HCD) activation (EThcD) to fragment HR Gd-glycopeptides to identify glycosylation sites ( Fig. 2) .
To increase the throughput of O-glycomic profiling of IgA1, we developed an in-house automated program, the Glycan Analyzer (MKI, Tokyo, Japan), to identify and quantify IgA1 O-glycoforms.
MS profiling of IgA1 HR O-glycoforms.
As susceptibility for IgAN is influenced by genetic background, and prevalence of IgAN is low in individuals of African ancestry, we used serum from healthy black subjects 39 . We have next tested our optimized bioinformatic solution by analyzing serum IgA1 isolated from 10 healthy subjects. Purified serum IgA1 was incubated with neuraminidase and then digested by trypsin. The neuraminidase treatment simplified the glycan structure and reduced the structural variety of attached glycans from six to two forms (i.e., GalNAc and GalNAc-Gal; Fig. 1b ). The resultant HR (glyco)peptides were then analyzed by using on-line LC-HRMS. Based on the potential number of GalNAc (n = 0-9, 203.0794 Da) and Gal (n = 0-9, Table 1 . HR glycoforms with 4 GalNAc and 4 Gal residues and HR with 5 GalNAc and 4 Gal residues were the two most abundant O-glycoforms (26.82% and 25.88%, respectively; P = 0.736). HR glycoforms with three to six O-glycan chains were observed; nine variants of Gd O-glycoforms with up to three Gd O-glycans were identified and designated as 1 Gd, 2 Gd, and 3 Gd. The median percentage of Gd O-glycan was 57.61% (54.17-61.95), on using Glycan Analyzer, and seemed to have some individual variation. To assess the performance of the automated analyses, we also performed manual analysis of the data and found that the RA values determined by Glycan Analyzer correlated well with the manually determined RA values (R 2 = 0.993, P < 0.001) ( Fig. 4b ).
Quantitative assessment of Gd O-glycan sites in IgA1 HR. After removal of disaccharides (GalNAc-Gal) from HR by O-glycanase, the number of IgA1 HR (glyco)peptides was reduced from 12 to 4; these HR variants corresponded to the naked (i.e., fully deglycosylated) HR peptide, and HR glycopeptides with one to three Gd O-glycans (Fig. 5 ). The XIC of each precursor ion is shown in Fig. 5 Tables S3-S5 ). To identify potential isomeric structure(s) based on the alternative attachment sites of the GalNAc residue(s) 38 , the detection time of each product ion was determined by generating the XIC (Supplementary Figs. S1-S3). After assigning the glycan attachment sites, XIC of each Gd O-glycopeptide isomer was analyzed and expressed as the percentage against all Gd O-glycopeptides (Fig. 6 ).
The XIC of 1 Gd O-glycoform (m/z 877.4123) showed a bimodal peak ( Fig. 6a ). EThcD fragmentation clearly indicated that 1 Gd O-glycoform eluting early (section 1 in Fig. 6a (Fig. 6b) . The predominant form Supplementary Fig. S4 ).
Discussion
In the current study, we devised a novel protocol for quantitative and qualitative profiling of Gd O-glycans in the IgA1 HR. We then used this protocol to successfully profile O-glycans in the IgA1 HR in healthy individuals, laying groundwork for studies of IgA1-related pathologies.
As determined by anti-Gd-IgA1 mAbs and GalNAc-specific lectins, the serum levels of Gd-IgA1 are elevated in individuals with IgAN and glomerular immunodeposits in these individuals are enriched for Gd-IgA1. As anti-Gd-IgA1 mAbs recognize Gd O-glycans located only at a specific site(s), quantitative assessment of Gd sites is needed to identify IgA1 HR O-glycoforms that are disease-specific. Because O-glycan synthesis occurs in a step-wise manner, O-glycoforms in the IgA1 HR exhibit wide diversity with respect to the attachment site, the number of O-glycan chains, and O-glycan structure (Fig. 1) . Such diversity generates analytical complexity. To address this issue, we developed a deglycosylation approach to simplify the O-glycoform structure before analysis. The ultimate application of the method is determining the differences in the amount of Gd O-glycans and their attachment sites in IgA1 from patients with IgA1-related disease, such as IgAN, and control individuals. This will only be possible by using a high-throughput protocol focusing on Gd O-glycans. Indeed, the protocol for quantitative profiling of IgA1 HR O-glycoforms devised in the current study reduced the structural variety of O-glycans from six to two structures ( Fig. 1 ) and the neuraminidase treatment incorporated in the protocol enabled HR O-glycopeptides profiling (the number and structure of the O-glycan chains). Furthermore, Glycan Analyzer, an in-house developed automated program, assisted the high-throughput quantitative analysis of the IgA1 HR O-glycoforms.
To investigate the attachment sites of Gd O-glycans, we analyzed all (nine) HR O-glycoforms, including Gd O-glycans, by EThcD tandem MS to localize the Gd O-glycan attachment sites (Fig. 4a ). Previously, we used three www.nature.com/scientificreports www.nature.com/scientificreports/ most likely because of insufficient charge density 36, 37 . In the current workflow, the O-glycanase digestion removed all but Gd O-glycans from the HR (Fig. 2) , reducing the minimum number of target precursor ions and enhancing their intensity for EThcD tandem MS. This modification allowed a successful quantitative assessment of the Gd O-glycan attachment sites in a single preparation of IgA1 HR.
The attachment sites of O-glycans in circulating IgA1 were determined by Mattu et al. 12 to be T 225, T 228 , S 230 , S 232 , and T 236 . Five O-glycosylation sites in IgA1 myeloma proteins, Gd-IgA1 mimics, have been reported 37 the frequent sites of Gd attachment are S 230 and T 236 . We further identified a sixth native site of O-glycosylation at T 233 , as well as isomers with different glycan positions and glycan-chain structures 38 . Our EThcD fragmentations of 1, 2, and 3 Gd O-glycoforms clearly showed that the most frequent site for Gd O-glycans was T 236 , followed by S 230 , T 233 , T 228 , and S 232 . T 225 was not a site for Gd O-glycan in IgA1 from any healthy individual in this study. Gal deficiency occurs mainly in the positions previously reported to be variably glycosylated and it is rare at sites that are consistently predominantly glycosylated. KM55, a mAb recently used for detection of Gd-IgA1, recognizes T 225 and/or T 233 in synthetic HR peptides 40 . However, it remains unclear whether this antibody recognizes a specific stereoscopic structure(s) of Gd-IgA1 with Gal-deficient sites at T 225 and/or T 233 . Comparison of serum level of Gd-IgA1 measured by Gd-IgA1 mAb ELISA and glycoprofiling generated by our new workflow would help identify specific IgA1 O-glycoforms elevated in IgAN. Furthermore, we can directly detect the specifically elevated Gal-deficient site(s) in IgA1 from IgAN patients by comparing the XIC of the three precursor ions in our approach between healthy subjects and IgAN patients.
In the current study, we identified 12 O-glycoforms of the desialylated serum IgA1 HR from healthy subjects, with three to six O-glycan chains attached per HR. The frequently occurring O-glycoforms were 4 GalNAc 4 Gal and 5 GalNAc 4 Gal, followed by 4 GalNAc 3 Gal, 5 GalNAc 3 Gal, 5 GalNAc 5 Gal. The most abundant Gd O-glycoform was 1 Gd O-glycoform, which accounted for approximately 40% of IgA1 (Table 1 and Supplementary  Table S2 ). By using on-line LC EThcD tandem MS, we elucidated the isomers of Gd O-glycan attachment sites for the 1-3 Gd O-glycopeptides. The main sites for Gd O-glycan attachment in 1 Gd O-glycoform were T 236 and S 230 . The XIC of 1 Gd O-glycoform showed a bimodal peak. The early peak, accounting for 62.9% of 1 Gd O-glycoform, mostly contained O-glycoforms with Gd O-glycan attached at T 236 and the late peak, accounting for 37.1% of 1 Gd O-glycoform, mostly contained molecules with O-glycan at S 230 . The Gd O-glycoforms with O-glycan attached at T 228 and T 236 were generally detected in the early phase of LC, as shown in Fig. 6 . Based on the properties of reversed-phase LC, the glycopeptides eluting in the early phase are more hydrophilic. A proline-rich segment www.nature.com/scientificreports www.nature.com/scientificreports/ (the PPTP motif) is present in the vicinity of residues T 228 and T 236 . Because proline is a hydrophobic amino acid, the attachment of GalNAc to T 228 and T 236 is highly likely to change the hydrophobic nature of HR, to a more hydrophilic nature. Furthermore, proline is thought to impact the protein architecture because its ring structure renders it more conformationally restricted than the other amino acids. Proline has a much greater propensity than other naturally occurring amino acids to form cis-amide bonds 41 . By contrast, a glycosylated S/T residue frequently alters the conformation of C-terminal proline to a trans conformation 42 . The attachment of GalNAc to T 228 and T 236 may also be important for the alteration of protein hydrophilic-hydrophobic nature and architecture for serum IgA1.
As a limitation of the developed method, we were not able to detect the attachment sites of galactosylated O-glycan chains. However, the pathogenesis of IgAN probably involves a specific Gd site 40 . In the context of investigating disease-specific Gd sites, removal of galactosylated O-glycans by sequential deglycosylation represents a considerable advantage for detecting the Gd O-glycan attachment sites. Furthermore, the function of proteins with clustered O-glycans, e.g., immunoglobulins, mucins, and some bacterial cell-surface glycoproteins, is under-investigated because of the glycoprotein complexity. The protocol presented in the current study lays the framework for a successful definition of the attachment sites and overall microheterogeneity of such proteins.
In conclusion, the new workflow, involving a high-resolution LC-MS with ETD tandem MS following a removal of galactosylated O-glycans, could be a powerful tool for the identification of specific glycoforms and specific Gd O-glycan attachment sites in IgA1 of individuals with IgAN.
Materials and Methods
Ethical approval. All experimental protocols were approved by Institutional Review Board (IRB) of Fujita Health University (approved number HM18-421). Informed consent was obtained from all subjects, and all methods were performed in accordance with the relevant guidelines and regulations. Serum sample collected from consented healthy donors under IRB-approved protocols in use at FDA-licensed donor centers (Bioreclamation IVT, Westbury, NY).
Purification of IgA1 and sample preparation for MS analysis. Polymeric IgA1 (Mce1) myeloma
protein was isolated from plasma of a patient with IgA1 myeloma, as described previously 38 . IgA1 was purified from 100 μl of serum of 10 black healthy subjects (30249993, Bioreclamation IVT, Westbury, NY) by using affinity chromatography with anti-human IgA (0855068, Cappel Laboratories, Cochranville, PA, USA) coupled to a cyanogen bromide-activated Sepharose column. Purified samples were stored aliquoted at −80 °C 38 . For IgA HR O-glycoform profiling, 5 μg of purified IgA1 proteins were treated with 2.5 mU neuraminidase (GK80040, ProZyme, Hayward, CA, USA) in 50 mM sodium phosphate, pH 6.0, at 37 °C, overnight. To detect Gd O-glycan attachment sites, purified IgA1 proteins were treated with an IgA-specific protease from Clostridium ramosum AK183 (a recombinant enzyme produced in Escherichia coli) 37 . Then, 5 μg of digested protein were treated with 2.5 mU neuraminidase. To remove disaccharides from HR glycopeptides, the digests were treated overnight with 40,000 U O-glycanase from Enterococcus faecalis (P0733, New England BioLabs, Ipswich, MA, USA) at 37 °C. To compare deglycosylation efficacy, 40,000 U O-glycanase from Enterococcus faecalis and 1.25 mU O-glycanase from Streptococcus pneumoniae (GK80090, Agilent, Santa Clara, CA, USA) were tested using polymeric IgA1 myeloma protein after neuraminidase treatment. Before MS analysis, disulfide bridges in the samples were reduced by incubating with 20 mM DTT for 15 min at room temperature and the samples were digested by trypsin (GK80040, Promega, Madison, WI, USA) (enzyme-to-substrate ratio of 1:50) in 100 mM NH 4 HCO 3 , pH 8.3, at 37 °C, overnight. The digests were desalted by passing through C18 spin columns (89873, Thermo Fisher Scientific, San Jose, CA, USA) and the solvent was removed by evaporating using a SpeedVac.
LC-MS analysis for profiling of IgA HR O-glycoforms.
On-line LC was performed using an EASY-nLC 1000 system (Thermo Fisher Scientific). For the analysis, 500 ng of desialylated and trypsin-digested IgA1 was loaded onto C18 EASY-Spray column (75 μm × 15 cm, 2.1 μm, 100 Å, Thermo Fisher Scientific). The digests were eluted using an acetonitrile gradient from 0% to 35% in 0.1% formic acid over 30 min at a flow rate of 300 nl/min. Hybrid quadrupole mass filter/linear ion trap/orbitrap MS (Orbitrap Fusion, Thermo Fisher Scientific) was alternated between a full orbitrap MS scan (m/z 500-1,700) at a resolving power of 120,000, the S-lens radio frequency level set at 60%, and a subsequent MS/MS scan of the abundant precursor ions.
EThcD tandem MS analysis for the detection of Gd O-glycan attachment sites.
After a sequential treatment of IgA1 by the IgA-specific protease (AK183), neuraminidase, O-glycanase, and trypsin (as described above), a desalted preparation corresponding to 2 μg of a mixture of IgA1 from 5 subjects was loaded onto on-line LC system for each target precursor ion measurement. The samples were eluted using an acetonitrile gradient from 11% to 18% in 0.1% formic acid over 20 min, at a flow rate of 300 nl/min. The mass spectrometer was set to target mass mode to automatically switch between MS and MS/MS acquisition. Full-scan MS spectra (m/z 780-1,200) were acquired using the Orbitrap analyzer at a resolution of 120,000, with a target value of charges (automatic gain control) of 4 × 10 5 .
For EThcD experiments, three trivalent cations corresponding to HR with one Gd O-glycan (m/z 877.7456), HR with two Gd O-glycan (m/z 945.4388), and HR with three Gd O-glycan (m/z 1,013.1319) were set as precursor ions. These ions were isolated by using an isolation window (m/z 3) and subsequently subjected to ETD. ETD reaction time was set to 50 ms, ETD reagent target value was set to 1 × 10 6 , and the maximum ETD reagent injection time was set to 200 ms. ETD supplemental activation collision energy type was EThcD (25% for HR with one GalNAc residue, 28% for HR with two GalNAc residues, 32% for HR with three GalNAc residues). Although three fragmentation approaches, e.g., ETD only, EThcD, or ETciD, were tested for HR and 1-3 Gd O-glycoforms, we could confirm sufficient fragmentation only by EThcD. This is similar to the original analysis of IgA1 O-glycsylation by activated
